Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

Inclusion Criteria: \- Parents/guardians must sign informed consent; Must be males or females whose age are 18 to 75 years old; Clinical diagnosis of chronic kidney disease on maintenance hemodialysis with secondary hyperparathyroidism; iPTH must be equal or higher than 300Pg/ml; Must not have received Calcimimetics(for example, Cinacalcet) within 6 months prior to enrollment; Must have been on maintenance hemodialysis 3 times weekly (TIW) for at least 3 months(12 weeks) prior to enrollment and must be expected to remain on hemodialysis for the duration of the study; Over 2-year life expectancy. Exclusion Criteria: \- Hypocalcemia \[Corrected serum calcium level less than 2.1mmol/L(8.4mg/dL); History of gastrointestinal bleeding or peptic ulcer disease and possibility of deterioration or recurrence; Severe heart disease; Epilepsy risk or history of epilepsy; Hypersensitivity to Cinacalcet; Drug abuse/addiction; Plan to receive renal transplantation within 52 weeks; Pregnant or lactating women; Pregnancy plan within 1 years, or no guarantee on taking effective contraceptive measures within 1 year after enrollment; Participated in other clinical trials within 4 weeks prior to enrollment; Received parathyroidectomy within 24 weeks prior to enrollment; Investigator judgment that patients are not suitable to enroll.